Year 2023 / Volume 115 / Number 11
Original
The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab

608-614

DOI: 10.17235/reed.2023.9491/2023

Pilar Navajas Hernández, Pilar del Pino Bellido, Laura Lorenzo González, Concepción González Rodríguez, Antonio Pérez Pérez, Federico Argüelles Arias,

Abstract
Background: the success of strategies with earlier anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) have been shadowed by the development of anti-drug antibodies that reduce their effectiveness. The HLA-DQA1*05 allele has been shown to increase the risk of immunogenicity to anti-TNF drugs by approximately two-fold. The negative impact of this allele has not been fully investigated for newer biotherapies. Objective: whether the presence of the HLA-DQA1*05 allele is associated with a reduction of response to ustekinumab and vedolizumab was investigated. Material and methods: the impact of HLA-DQA1*05 on disease activity in 93 patients with IBD, treated with ustekinumab (n = 39) or vedolizumab (n = 54) was investigated in a retrospective cohort study. Treatment response and remission was assessed at 6 and 12 months for ustekinumab, and up to 18 and 24 months for vedolizumab, using Harvey-Bradshaw index (Crohn’s disease) and Mayo score (ulcerative colitis). Results: the HLA-DQA1*05 allele was found in 35.9 % and 38.9 % of patients treated with ustekinumab and vedolizumab, respectively. Clinical response was not affected by the presence of the HLA-DQA1*05 allele for both treatment groups. Conclusions: in contrast to anti-TNF drugs, HLA-DQA1*05 presence does not correlate with the decreased response to ustekinumab or vedolizumab.
Lay Summary
Studies suggest that the presence of a genetic allele (HLA-DQA1*05) has been implicated in a worse response and development of antibodies to certain biologic therapies, in particular anti-TNFs (the most commonly used drugs in inflammatory bowel disease). Newer drugs used more recently in IBD include ustekinumab and vedolizumab. There is no evidence that this genotype is associated with response to these drugs, which is why the aim of our study was to evaluate whether the presence of the HLA-DQA1*05 allele is associated with a reduced response to ustekinumab and vedolizumab. To do so, we conducted a retrospective study, in which we concluded that the clinical response to these drugs was not affected by the presence of the HLA-DQA1*05 allele in both treatment groups in contrast to the anti-TNF drugs, HLA-DQA1*05 carriage does not correlate with decreased response to ustekinumab or vedolizumab.
Share Button
New comment
Comments
No comments for this article
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Experience with ustekinumab in reservoir Crohn's disease

DOI: 10.17235/reed.2021.8457/2021

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Navajas Hernández P, del Pino Bellido P, Lorenzo González L, González Rodríguez C, Pérez Pérez A, Argüelles Arias F, et all. The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab. 9491/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1584 visits.
This article has been downloaded 150 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 25/01/2023

Accepted: 17/05/2023

Online First: 14/06/2023

Published: 13/11/2023

Article revision time: 99 days

Article Online First time: 140 days

Article editing time: 292 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology